What it is

DayZero Wharton's Jelly Matrix is an extracellular vesicle preparation derived from Wharton's Jelly, the connective tissue found within the human umbilical cord. It is manufactured by ZEO ScientifiX, Inc., a Florida-based regenerative biologics company and SEC-registered public filer. The label designation "300B" refers to the extracellular vesicle particle count stated on the vial — a neutral manufacturing specification, not a clinical dosing recommendation.

Source & manufacturing

Wharton's Jelly is a birth tissue (perinatal) source. This material is allogeneic — meaning it is donor-derived, not sourced from the patient receiving it. ZEO ScientifiX holds patents on perinatal-fluid and birth-tissue processing techniques and maintains an active clinical research portfolio. TC Regen sources this material from ZEO ScientifiX as a documented supplier.

How TC Regen uses it

At TC Regen Naples and TC Regen Fort Myers, DayZero Wharton's Jelly Matrix is administered exclusively under the direct supervision of a licensed physician. Whether this material is included in a patient's plan is a diagnosis-driven decision — a physician evaluates each patient's condition individually before any determination is made. No protocol is applied uniformly across patients.What you might discover.

Regulatory status

This product is not FDA-approved. Wharton's Jelly-derived preparations are allogeneic birth-tissue biologics subject to the highest level of FDA scrutiny. TC Regen administers this material in compliance with Florida's Stem Cell Therapy Act, which mandates written informed consent and explicit disclosure that the therapy is not FDA-approved prior to any administration. No therapeutic outcomes are promised or implied.